Salvianolic acid B ameliorates CNS autoimmunity by suppressing Th1 responses. (21st April 2016)

• Record Type: Journal Article
• Authors: Dong, Zhihui; Ma, Dihui; Gong, Ye; Yu, Tingmin; Yao, Gang
• Is Part Of: Neuroscience letters. Volume 619(2016)
• Page Start: 92
• Page End: 99
• Publication Date: 2016-04-21
• Subjects: Experimental autoimmune encephalomyelitis -- Multiple sclerosis -- Salvianolic acid B -- Salvia miltiorrhiza; Neurology -- Periodicals; Neurology -- Periodicals; Research -- Periodicals; Neurologie -- Périodiques; Neuroanatomie -- Périodiques; Neuropharmacologie -- Périodiques; Neurophysiologie -- Périodiques; Neurology; Periodicals; Electronic journals; 617.48
• DOI: 10.1016/j.neulet.2016.01.008
• Languages: English
• ISSNs: 0304-3940

Abstract

Highlights: Salvianolic acid B (Sal B) effectively reduced EAE severity and inhibited the usual loss of body weight. Sal B treatment downgraded the infiltration of inflammatory cells and limited astrogliosis. Sal B ameliorates EAE through blocking Th1 responses. Abstract: Experimental autoimmune encephalomyelitis (EAE), the animal model of multiple sclerosis (MS), is a Th1 and Th17 cell-mediated CNS autoimmune disease. Therefore, immune regulation is a key target for therapy. Salvianolic acid B (Sal B) is a major water-soluble bioactive component of the famous traditional Chinese medicine Salvia miltiorrhiza, which is notable for its anti-oxidative and anti-inflammatory effects. Thus Sal B, by impairing Th1 or Th17 responses in EAE/MS, might ameliorate the crippling symptoms. Here we show that the intraperitoneal administration of 30 mg/kg Sal B daily for 14 days after the onset of MOG-induced EAE in mice effectively reduced its severity. Additionally, Sal B treatment downgraded the infiltration of inflammatory cells, limited astrogliosis and blocked Th1 responses other than that of Th17. These results indicated that Sal B may serve as an effective therapeutic agent for MS/EAE by inhibiting Th1 cell responses.